Should the Drug Giant cover-up raise questions about your flea and tick product?

Under mounting pressure from the Food and Drug Administration (FDA), Bayer Corporation discontinued the sale of its hugely profitable drug Trasylol in November 2007.

Trasylol, a blood clotting drug used during heart surgery to control bleeding, has been given to more than four and a half million people around the world. About 1.5 million Americans received Trasylol during its 14 years on the US market.

The studies found that patients who received Trasylol during heart bypass, heart valve replacement, and other heart surgeries were more likely to die than patients who received other available blood clotting medications. The deaths were due to heart failure, kidney failure, heart attacks and strokes that patients suffered after surgery.

In 2007, Bayer designed a major Canadian trial to show that Trasylol was better than other drugs at controlling bleeding. However, the trial was terminated due to an increase in deaths among heart surgery patients using the drug. Patients who received Trasylol had a 50 percent higher risk of dying compared to patients who received other medications.

What are a few thousand deaths between friends?

60 minutes reported in February 2008 that Bayer had known about Trasylol’s safety concerns for decades and about the abnormally high incidents of deaths associated with the drug since 2006. However, Bayer continued to aggressively market the drug, raising more than $ 300 million annually . The FDA allowed Trasylol to remain on the market, contributing to an estimated 1,000 deaths per month during the 22 months prior to its recall.

Tea 60 minutes The report went on to describe Bayer’s own internal study evaluating the risk of death in patients from Trasylol. A Harvard professor who was included on Bayer’s payroll examined the medical records of nearly 70,000 patients. What the professor found was that the patients who received Trasylol were at increased risk of acute kidney failure.

Bayer withheld this study from the FDA during a Trasylol safety review in 2006. The pharmaceutical giant further enchanted the FDA to allow Trasylol to remain on the market. It took more than a year before the FDA reviewed Trasylol’s adverse effects again. Ultimately, the FDA withdrew the drug but did not impose any fines or penalties on Bayer.

What does this have to do with fleas and ticks on cats and dogs?

Another way Bayer works wonders is with its insecticide Imidacloprid, the active ingredient in the Advantage Flea & Tick treatment for dogs and cats. Laboratory test results on file with the US Environmental Protection Agency show that imidycloprid is neurotoxic to dogs and other laboratory animals, and also causes a disruption in coordination, shortness of breath, reduced birth weight, increased birth defects, and thyroid lesions.

Of course, Bayer has remained silent like a stalactite on these adverse health effects of our precious pets. Could this be another 60 minutes report in process?

Sooner or later, responsible cat and dog lovers must ask themselves the question: Am I relying too much on Big Pharma with the safety of my best friends? Sooner or later you will have to wonder if toxic chemicals are really necessary when safe and natural flea and tick treatments are available.

What is my advice? You can’t ask questions too soon, but can ask them too late. Find out now why pet lovers around the world are turning to TripleSure Natural Flea and Tick Spray for Dogs and Cats.